WallStSmart

Biodesix Inc (BDSX)vsDanaher Corporation (DHR)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Danaher Corporation generates 27661% more annual revenue ($24.57B vs $88.50M). DHR leads profitability with a 14.7% profit margin vs -39.9%. DHR earns a higher WallStSmart Score of 60/100 (C).

BDSX

Avoid

30

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.0

DHR

Buy

60

out of 100

Grade: C

Growth: 4.0Profit: 6.0Value: 7.3Quality: 6.3
Piotroski: 4/9Altman Z: 2.36
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BDSX.

DHRSignificantly Overvalued (-38.6%)

Margin of Safety

-38.6%

Fair Value

$135.07

Current Price

$187.15

$52.08 premium

UndervaluedFair: $135.07Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BDSX1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
40.8%10/10

Revenue surging 40.8% year-over-year

DHR4 strengths · Avg: 8.3/10
Market CapQuality
$134.43B9/10

Large-cap with strong market position

Price/BookValuation
2.5x8/10

Reasonable price relative to book value

Operating MarginProfitability
22.2%8/10

Strong operational efficiency at 22.2%

Free Cash FlowQuality
$1.75B8/10

Generating 1.7B in free cash flow

Areas to Watch

BDSX4 concerns · Avg: 2.5/10
EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Market CapQuality
$146.64M3/10

Smaller company, higher risk/reward

Return on EquityProfitability
-3.8%2/10

ROE of -3.8% — below average capital efficiency

Profit MarginProfitability
-39.9%1/10

Currently unprofitable

DHR3 concerns · Avg: 3.7/10
P/E RatioValuation
37.7x4/10

Premium valuation, high expectations priced in

Revenue GrowthGrowth
4.6%4/10

4.6% revenue growth

Return on EquityProfitability
7.0%3/10

ROE of 7.0% — below average capital efficiency

Comparative Analysis Report

WallStSmart Research

Bull Case : BDSX

The strongest argument for BDSX centers on Revenue Growth. Revenue growth of 40.8% demonstrates continued momentum.

Bull Case : DHR

The strongest argument for DHR centers on Market Cap, Price/Book, Operating Margin. PEG of 1.23 suggests the stock is reasonably priced for its growth.

Bear Case : BDSX

The primary concerns for BDSX are EPS Growth, Market Cap, Return on Equity.

Bear Case : DHR

The primary concerns for DHR are P/E Ratio, Revenue Growth, Return on Equity.

Key Dynamics to Monitor

BDSX profiles as a hypergrowth stock while DHR is a value play — different risk/reward profiles.

DHR carries more volatility with a beta of 0.96 — expect wider price swings.

BDSX is growing revenue faster at 40.8% — sustainability is the question.

DHR generates stronger free cash flow (1.7B), providing more financial flexibility.

Bottom Line

DHR scores higher overall (60/100 vs 30/100). Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Biodesix Inc

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Biodesix, Inc. operates a data-driven diagnostic solutions company in the United States. The company is headquartered in Boulder, Colorado.

Danaher Corporation

HEALTHCARE · DIAGNOSTICS & RESEARCH · USA

Danaher Corporation is an American globally diversified conglomerate with its headquarters in Washington, D.C.. The company designs, manufactures, and markets professional, medical, industrial, and commercial products and services. The company's 3 platforms are Life Sciences, Diagnostics, and Environmental & Applied Solutions.

Want to dig deeper into these stocks?